France’s Sanofi halts work on anti-Covid vaccine

COVID-19
Transmission electron microscope image of SARS-CoV-2, the virus that causes COVID-19, emerging from human cells. Credit: NIAID

French pharmaceutical giant Sanofi said Tuesday it was stopping work on an mRNA vaccine against COVID-19 despite positive test results as it lags behind rivals on producing a coronavirus shot.

The company said it would focus instead on another type of jab it is developing with British drug maker GlaxoSmithKline and which is in the final phase of human trials.

Sanofi’s mRNA vaccine—the ground-breaking technology used by rivals Pfizer/BioNTech and Moderna—had positive results in phase one and two of clinical trials, the firm said.

But Sanofi said it will not take it into the third and final phase, arguing that it would arrive too late to market with 12 billion COVID doses due to be produced by the end of the year.

Instead, the company will use the mRNA technology for vaccines against other pathogens, including the flu.

“The need is not to create new COVID-19 mRNA vaccines, but to equip France and Europe with an arsenal of messenger RNA vaccines for the next pandemic, for new pathologies,” Sanofi’s vice-president for vaccines, Thomas Triomphe, told AFP.

“There is no public health need for another messenger RNA vaccine” against COVID-19, he added.

Results from phase three trials of the other vaccine developed with GlaxoSmithKline are expected before the end of 2021.

The firms are combining a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK’s adjuvant technology, a substance that bolsters the immune response triggered by a vaccine.

Fighting flu and malaria

Messenger RNA works by providing human cells with the genetic instructions to make a surface protein of the coronavirus, which trains the immune system to recognise the real virus.

Sanofi said initial results for the mRNA product showed antibodies were created by 91-100 percent of test participants two weeks after a second injection.

No side effects were observed and tolerance of the jab was comparable to other mRNA vaccines developed by Pfizer/BioNTech and Moderna.

The immune response from the Sanofi mRNA vaccine “is strong”, Triomphe said.

Sanofi had been working since March 2020 with Translate Bio, a US firm specialising in mRNA technology, and had even bought the biotech company for 2.7 billions euros ($3.2 billion) at the start of August.

Sanofi has already launched new tests for a seasonal flu vaccine and intends to start clinical trials next year.

The results from the COVID mRNA vaccine “will clearly help inform the path forward for our mRNA development programs,” said Sanofi’s global head of research and development, Jean-Francois Toussaint.

“Today, we have a promising mRNA platform, which we’re taking to the next level in development, including moving to modified mRNA, and against other diseases, including flu.”

Germany’s BioNTech, which developed its coronavirus mRNA vaccine with US giant Pfizer, announced in July that it aimed to start trialling a malaria vaccine using mRNA technology.



© 2021 AFP

Citation: France’s Sanofi halts work on mRNA Covid vaccine (2021, September 28) retrieved 30 September 2021 from https://medicalxpress.com/news/2021-09-france-sanofi-halts-anti-covid-vaccine.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Note: This article have been indexed to our site. We do not claim ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Israel says US booster plan supports its own aggressive push thumbnail

Israel says US booster plan supports its own aggressive push

A 14-year-old Israeli receives a booster shot of the coronavirus vaccine at Clalit Health Service's center in the Cinema City complex in Jerusalem, Wednesday, Sept. 22, 2021. Israel is pressing ahead with its aggressive campaign of offering coronavirus boosters to almost anyone over 12 and says its approach was further vindicated by a U.S. decision…
Read More
FDA Adds Warning of Intestinal Blockages to Ozempic Label thumbnail

FDA Adds Warning of Intestinal Blockages to Ozempic Label

Please enable cookies. Error 1005 Ray ID: 82b70771cfcd861b • 2023-11-25 04:08:11 UTC What happened? The owner of this website (www.webmd.com) has banned the autonomous system number (ASN) your IP address is in (47583) from accessing this website. Was this page helpful? Thank you for your feedback! Cloudflare Ray ID: 82b70771cfcd861b • Your IP: 89.117.245.16 •
Read More
Prescribe fewer antidepressants, and for shorter periods, doctors advised thumbnail

Prescribe fewer antidepressants, and for shorter periods, doctors advised

Credit: Unsplash/CC0 Public Domain Doctors should prescribe fewer antidepressants and for shorter periods of time, because of the ongoing uncertainties about their effectiveness and the potential severity and durability of the withdrawal symptoms associated with them, suggests a review of the evidence on antidepressant use, published online in the Drug and Therapeutics Bulletin. The use…
Read More

Linda Evangelista Claims This Popular Cosmetic Procedure Left Her ‘Brutally Disfigured’

Supermodel Linda Evangelista says that CoolSculpting, a popular cosmetic procedure, did the opposite of what it claimed to do—and left her “permanently deformed.” In an Instagram post, Evangelista revealed new details about what happened and announced she is suing the company behind CoolSculpting.“Today I took a big step towards righting a wrong that I have…
Read More
Congress gives $10M to DoD, Philips to advance AI-driven disease prediction thumbnail

Congress gives $10M to DoD, Philips to advance AI-driven disease prediction

New funding from Congress's Accelerate the Procurement and Fielding of Innovative Technologies initiative will enable the Department of Defense Rapid Assessment of Threat Exposure project with additional investment, based on its success in demonstrating that the use of artificial intelligence to leverage data from wearables could predict COVID-19 and other infections 2.3 days prior to
Read More
Index Of News
Total
0
Share